Canada Life’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $239K | Buy |
11,390
+767
| +7% | +$17.3K | ﹤0.01% | 1580 |
|
|
2025
Q4 | $245K | Sell |
10,623
-16,309
| -61% | -$536K | ﹤0.01% | 1601 |
|
|
2025
Q3 | $817K | Buy |
26,932
+534
| +2% | +$16K | ﹤0.01% | 1491 |
|
|
2025
Q2 | $962K | Buy |
26,398
+2,937
| +13% | +$106K | ﹤0.01% | 1446 |
|
|
2025
Q1 | $851K | Buy |
23,461
+308
| +1% | +$12.8K | ﹤0.01% | 1480 |
|
|
2024
Q4 | $972K | Sell |
23,153
-647
| -3% | -$32.1K | ﹤0.01% | 1476 |
|
|
2024
Q3 | $1.32M | Sell |
23,800
-2,448
| -9% | -$125K | ﹤0.01% | 1442 |
|
|
2024
Q2 | $1.08M | Sell |
26,248
-1,213
| -4% | -$51.8K | ﹤0.01% | 1485 |
|
|
2024
Q1 | $1.28M | Sell |
27,461
-1,444
| -5% | -$68.1K | ﹤0.01% | 1429 |
|
|
2023
Q4 | $1.37M | Buy |
28,905
+1,409
| +5% | +$54.6K | ﹤0.01% | 1407 |
|
|
2023
Q3 | $980K | Buy |
27,496
+6,448
| +31% | +$255K | ﹤0.01% | 1484 |
|
|
2023
Q2 | $977K | Buy |
21,048
+1,319
| +7% | +$61.2K | ﹤0.01% | 1498 |
|
|
2023
Q1 | $792K | Sell |
19,729
-5,931
| -23% | -$255K | ﹤0.01% | 1567 |
|
|
2022
Q4 | $1.2M | Buy |
25,660
+15,873
| +162% | +$624K | ﹤0.01% | 1458 |
|
|
2022
Q3 | $404K | Buy |
9,787
+6,234
| +175% | +$320K | ﹤0.01% | 1726 |
|
|
2022
Q2 | $212K | Buy |
3,553
+69
| +2% | +$4.25K | ﹤0.01% | 1808 |
|
|
2022
Q1 | $268K | Sell |
3,484
-226
| -6% | -$15.7K | ﹤0.01% | 1830 |
|
|
2021
Q4 | $311K | Buy |
3,710
+69
| +2% | +$5.61K | ﹤0.01% | 1799 |
|
|
2021
Q3 | $330K | Hold |
3,641
| – | – | ﹤0.01% | 1810 |
|
|
2021
Q2 | $347K | Sell |
3,641
-328
| -8% | -$34.2K | ﹤0.01% | 1819 |
|
|
2021
Q1 | $448K | Buy |
3,969
+210
| +6% | +$28.6K | ﹤0.01% | 1773 |
|
|
2020
Q4 | $518K | Hold |
3,759
| – | – | ﹤0.01% | 1744 |
|
|
2020
Q3 | $309K | Hold |
3,759
| – | – | ﹤0.01% | 1792 |
|
|
2020
Q2 | $293K | Hold |
3,759
| – | – | ﹤0.01% | 1814 |
|
|
2020
Q1 | $168K | Hold |
3,759
| – | – | ﹤0.01% | 1856 |
|
|
2019
Q4 | $159K | Buy |
+3,759
| New | +$155K | ﹤0.01% | 1974 |
|
|
2019
Q3 | – | Sell |
-7,036
| Closed | -$446K | – | 2003 |
|
|
2019
Q2 | $446K | Buy |
7,036
+460
| +7% | +$29.3K | ﹤0.01% | 1809 |
|
|
2019
Q1 | $454K | Buy |
6,576
+1,232
| +23% | +$70.4K | ﹤0.01% | 1661 |
|
|
2018
Q4 | $224K | Hold |
5,344
| – | – | ﹤0.01% | 1901 |
|
|
2018
Q3 | $409K | Hold |
5,344
| – | – | ﹤0.01% | 1795 |
|
|
2018
Q2 | $411K | Sell |
5,344
-875
| -14% | -$56.5K | ﹤0.01% | 1792 |
|
|
2018
Q1 | $318K | Hold |
6,219
| – | – | ﹤0.01% | 1837 |
|
|
2017
Q4 | $288K | Buy |
6,219
+2,080
| +50% | +$102K | ﹤0.01% | 1871 |
|
|
2017
Q3 | $223K | Hold |
4,139
| – | – | ﹤0.01% | 1914 |
|
|
2017
Q2 | $257K | Hold |
4,139
| – | – | ﹤0.01% | 1863 |
|
|
2017
Q1 | $280K | Hold |
4,139
| – | – | ﹤0.01% | 1836 |
|
|
2016
Q4 | $292K | Hold |
4,139
| – | – | ﹤0.01% | 1810 |
|
|
2016
Q3 | $293K | Hold |
4,139
| – | – | ﹤0.01% | 1816 |
|
|
2016
Q2 | $202K | Buy |
4,139
+1,584
| +62% | +$102K | ﹤0.01% | 1889 |
|
|
2016
Q1 | $162K | Hold |
2,555
| – | – | ﹤0.01% | 1442 |
|
|
2015
Q4 | $287K | Hold |
2,555
| – | – | ﹤0.01% | 1098 |
|
|
2015
Q3 | $247K | Buy |
2,555
+755
| +42% | +$86.4K | ﹤0.01% | 1140 |
|
|
2015
Q2 | $184K | Hold |
1,800
| – | – | ﹤0.01% | 1420 |
|
|
2015
Q1 | $111K | Hold |
1,800
| – | – | ﹤0.01% | 1738 |
|
|
2014
Q4 | $79K | Buy |
+1,800
| New | +$82.5K | ﹤0.01% | 1893 |
|
Other funds holding RARE
VPM
VCM
RI
SI
BG
Canada Life's RARE Position: Q1 2026 in Review
Canada Life increased its Ultragenyx Pharmaceutical (RARE) stake by 7.2% in Q1 2026, buying an estimated $17.3K and bringing the position to 11,390 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #1580.
Canada Life first reported a position in RARE in Q4 2014 and has held it in 45 quarters since. The position peaked at $1.37M in Q4 2023. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.
- Canada Life held 11,390 shares of Ultragenyx Pharmaceutical worth $239K as of Q1 2026.
- Canada Life bought 767 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $17.3K.
- Ultragenyx Pharmaceutical made up ﹤0.01% of Canada Life's portfolio in Q1 2026, its #1580 holding.
- Canada Life first reported a position in Ultragenyx Pharmaceutical in Q4 2014 and has held it in 45 quarters since.
- Canada Life's Ultragenyx Pharmaceutical position peaked at $1.37M in Q4 2023.
- 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.
Based on Canada Life's 13F filing for Q1 2026, filed 14 May 2026.